GeNeuro Successfully Completes Phase 2a Clinical Study with Novel Approach to Treat Multiple Sclerosis   First in Class GNbAC1 mAb Targets Human Endogenous RetroVirus Geneva, Switzerland and Lyon / Archamps, France - ...

Geneva, Switzerland and Archamps, France, September 9, 2013 – Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that the U.S. Food and Drug Administration has approved the company’s Investigation ...

GeNeuro SA announces today the successful completion of its phase I clinical study with GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis. The randomized, doub ...